Feb 13 (Reuters) – Disc Medicine said on Friday the U.S. Food and Drug Administration has declined to approve its drug to treat a rare genetic disorder, sending its shares down 31.6% to $48.90.
The company was seeking approval for its experimental drug bitopertin as a treatment for patients with erythropoietic protoporphyria, a rare genetic metabolic disorder caused by a deficiency of the ferrochelatase enzyme. The major symptom of this disorder is hypersensitivity of the skin to sunlight.
(Reporting by Sneha S K; Editing by Vijay Kishore)
Brought to you by www.srnnews.com